Kenvue

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Kenvue (KVUE) reports strong Q2 earnings, eyes China growth

Kenvue's Q2 performance showcased robust net sales, organic growth, and strategic investments in key segments. The company's focus on consumer trust, supply chain enhancements, and capital allocation strategy underpin its resilience. Challenges include managing inflationary pressures and sustaining growth post-COVID, but opportunities in China and ongoing investments position Kenvue for future success.

Kenvue (KVUE) reports solid Q3 performance amidst segment challenges

Kenvue (KVUE) delivered a solid Q3 performance, showcasing strength in key segments despite challenges in others.
The company's strategic initiatives, focus on innovation, and outlook for growth opportunities position it well for future success.
Efforts to address challenges in specific segments and capitalize on opportunities demonstrate a proactive approach to sustaining growth and profitability.
Overall positive outlook on third-quarter results reflects the company's strong model, portfolio, and cash flow generation capabilities.

Kenvue reports mixed 2023 performance, focuses on growth strategies

Kenvue's 2023 performance saw organic growth but faced challenges in specific segments, leading to adjustments for 2024. The company aims to drive growth through operational efficiencies, increased brand investments, and a focus on consumer engagement. Challenges in U.S. in-store execution prompted a recovery plan and leadership changes.

Kenvue surpasses Q1 expectations, eyes China growth amid challenges

Kenvue's Q1 performance exceeded expectations, driven by key segments and brands.
Strategic focus on cost optimization, operational efficiency, and brand impact.
Challenges include stabilizing declining segments and managing hyperinflation impact.
Opportunities lie in growing China business, operational reinvention, and new leadership.

Kenvue reports solid Q2 performance and optimistic outlook for 2024

Kenvue's Q2 performance reflects steady growth and improved profitability, driven by strategic initiatives and strong brand performance. While cost management and increased marketing spend pose challenges, the company's focus on brand investment and long-term value creation offers promising opportunities for future growth and shareholder returns.

Kenvue reports Q3 growth, tackles Skin Health challenges, eyes savings

Kenvue's Q3 performance showed organic growth and strong financial metrics.
While facing challenges in the Skin Health segment, the company is focusing on recovery.
Investments in marketing and efficiency improvements highlight growth opportunities.
Executives addressed key questions on guidance, inventory levels, and growth strategies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Kenvue, Inc. is a consumer health company. It operates through the following business segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment includes cough, cold and allergy, pain care, digestive health, and smoking cessation. The Skin Health and Beauty segment offers face and body care and hair, sun and others. The Essential Health segment focuses on oral care, baby care, women's health and wound care. The company was founded on February 23, 2022 and is headquartered in Skillman, NJ.

Johnson & Johnson

Kenvue (NYSE: KVUE ) stock is in the news Monday after the company announced that Johnson & Johnson (NYSE: JNJ ) is selling its stake in the business. Kenvue has announced a secondary offering that will have Johnson & Johnson selling its entire stake of 182,329,550 shares of KVUE stock.

Johnson & Johnson Is Officially Getting Out of Kenvue (KVUE) Stock

Kenvue Inc.'s stock fell 1.8% early Monday, after the consumer-health business, which was spun out of Johnson & Johnson last year, announced plans for a secondary offering of 182.3 million shares.

Kenvue's stock falls after company announces 182.3 million secondary stock offering

Tylenol maker Kenvue said on Monday that Johnson & Johnson will offload its entire 9.5% stake in the company, about a year after the healthcare conglomerate spun off and listed its consumer health business.

J&J to exit Kenvue, a year after spinoff

SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue announced today the launch of a secondary underwritten public offering of 182,329,550 shares of its common stock.

Kenvue Announces Launch of Secondary Offering

Amcor Plc

Franklin Resources

J. M. Smucker

Want retirement to come a few years earlier than you'd planned? Orare you ready to retire now, but want an extra set of eyes on your finances?

4 Strong Buy Dividend Aristocrats Wall Street Loves Are Trading Just Above 52-Week Lows

Chevron

Federal Realty Investment Trust

Realty Income Corp

T. Rowe Price Group

"Dividend Aristocrats in the S&P 500 Index… have raised their annual payouts every year for at least 25 consecutive years."--Kiplinger.com/Investing.

4 Dividend Aristocrats To Buy In May Plus 4 To Watch

Just after beating profit estimates for the first quarter of 2024, Kenvue (NYSE: KVUE ) has announced plans to reduce its global workforce by 4%. Formerly a division of Johnson & Johnson (NYSE: JNJ ), the consumer health company is best known as the owner of the Tylenol and Band-Aids brands.

Kenvue Layoffs 2024: What to Know About the Latest KVUE Job Cuts

Kenvue Inc (NYSE:KVUE) shares moved higher after the Tylenol-maker posted better-than-expected first quarter earnings on Tuesday. Shares of the Johnson & Johnson (NYSE:JNJ) consumer healthcare spin-off company - whose brands also include Neutrogena, Listerine, Band-Aid, and Aveeno – added 5.1% at $19.84 late morning.

Kenvue shares rise on first quarter earnings beat

Kenvue Inc.'s stock KVUE, -0.63% jumped 4.7% early Tuesday, after the consumer health business that was spun out of Johnson & Johnson last year posted better-than-expected first-quarter earnings and announced plans to cut jobs. The company had net income of $296 million, or 15 cents a share, for the quarter, down rom $469 million, or 27 cents a share, in the year-earlier period.

Kenvue's stock jumps 4.7% after earnings beat and news company to cut 4% of global workforce

Kenvue beat Wall Street estimates for first-quarter profit on Tuesday, and said it would cut 4% of its global workforce amid the Tylenol and Band-Aid maker's efforts to expand its key brands.

Tylenol maker Kenvue beats quarterly profit estimates, to cut 4% jobs

SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) (“Kenvue”), today announced financial results for the fiscal first quarter ended March 31, 2024. “We entered 2024 with clear strategic priorities to reach more consumers, reinvent our ways of working to invest more behind our brands, and to foster a culture that rewards performance and impact,” said Thibaut Mongon, Chief Executive Officer. “We began executing against these priorities during the quarter, enabling a solid start to the year.

Kenvue Reports First Quarter 2024 Results

GE HealthCare Technologies Inc

Solventum Corporation

There's a lot of evidence suggesting that spinoff stocks are generally a good idea to watch. Following a split from their parent company, many such firms do well thanks to their efficiency and newly-found flexibility.

Investor Alert: Are These 3 Spinoff Stocks Destined to Sizzle or Fizzle?

AbbVie

Kimberly-Clark

Coca-Cola

Target

Since 1926, dividends have contributed approximately 32% of the total return for the S&P 500, while capital appreciations have contributed 68%. Therefore, sustainable dividend income and capital appreciation potential are essential for total return expectations.

5 Dividend King Blue-Chips That Lagged the Market Are Incredible May Buys

Few investment strategies have performed as well for as long as dividend investing. Numerous studies show that buying stocks that have initiated a dividend and then increased it over time beat all other stocks on the market.

7 Dividend Aristocrats Paying Sky-High Yields: April 2024

Albertsons Companies

CMS Energy

Genuine Parts

Altria

PepsiCo

Before considering which stocks to buy if inflation continues, it's good to remember the relationship between inflation and interest rates. The latest reading on CPI and PPI shows that the declining inflation rate may be ramping back up.

7 Stocks to Buy if Inflation Continues to Reign in 2024

Colgate-Palmolive

McDonald's

Marathon Petroleum

Microsoft

Sempra Energy

Walmart

Perhaps the biggest justification for steady stocks comes from an asset class completely unrelated to the equities market: cryptocurrencies. After the benchmark blockchain asset hit a record high earlier this year, the sector has struggled for traction.

Steady Eddies: 7 Rock-Solid Stocks to Anchor Your Portfolio in April

Dividend income can be a good way to bolster growth in your portfolio's value. Dividend Kings are companies that have paid and raised their dividend for at least 50 years.

Here Are My Top 5 Dividend Kings to Buy Right Now

Archer-Daniels-Midland Company

PPG Industries

Dividend stocks have a proven record of stock market outperformance. For nearly 100 years, income-generating stocks on the S&P 500 have beaten non-payers.

3 Dividend Kings Down 11% You'll Regret Not Buying on the Dip

An Illinois court late Friday ordered pharmaceutical giant Johnson & Johnson and Kenvue to pay $45 million to a family that alleged the companies' talcum-based baby powder led to the death of a relative diagnosed with a fatal cancer linked to asbestos exposure, the company's latest legal issue involving talc products.

Court Orders Johnson & Johnson And Kenvue To Pay $45 Million In Talcum Baby Powder Lawsuit

American Tower

Home Depot

JPMorgan Chase & Co

Kinder Morgan

While earlier discussions focused on the Federal Reserve's potential interest rate cuts, that's no longer a surefire proposition, thus warranting consideration for stocks for Fed hikes. Let's break this matter down.

Invest Like a Hawk: 7 Stocks to Own If the Fed Stays Tough

Con Ed

Exxon Mobil

Its products are sold under these brands: Exxon Esso Mobil  The Chemical Products segment manufactures and markets petrochemicals, including olefins, polyolefins, and intermediates.

6 Dividend Aristocrats to Buy for Reliable Passive Income

American States Water

Black Hills

California Water Service Group

Fortis

Hormel Foods

Leggett & Platt

Middlesex Water

National Fuel Gas

Northwest Natural Gas

SJW Group

United Bankshares

Universal Corp

"What is a Dividend King? A stock with 50 or more consecutive years of dividend increases."—suredividend.com. The 55 Dividend Kings screened as of April 10 represented 9 of 11 Morningstar Sectors. Broker targeted-top-ten net-gains ranged 15.19%-33.38% topped-by Middlesex Water, and SJW Group. By yield, Leggett tops-all. Top-ten April Kings: FRT, UBSI, FTS, BKH, NWN, CDUAF, MMM, UVV, MO, & LEG averaged 6.24% in yield.

55 April Dividend Kings: Buy 8, Watch 8

Kenvue (KVUE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Kenvue (KVUE) Could Beat Earnings Estimates Again

Kenvue (NYSE: KVUE ) has announced plans to lay off over 100 employees at one of its leading brands. Specifically, the prominent skincare, cosmetics and health company will be implementing job cuts at Neutrogena, a well-known name in the health and beauty space.

Kenvue Layoffs 2024: What to Know About the Latest Neutrogena Job Cuts

Air Products and Chemicals

Essex Property Trust

Fastenal

Medtronic

NextEra Energy

V.F.

Walgreens

"Dividend Aristocrats. in the S&P 500 Index… have raised their annual payouts every year for at least 25 consecutive years. "-- Kiplinger.com/Investing.

4 Dividend Aristocrats Signal Buy In April Plus 6 To Watch

News for Kenvue Stock (KVUE)